Abstract: A pharmaceutical composition comprising, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or a pharmaceutically acceptable derivative thereof in admixture with a pharmaceutical acceptable adjuvant or excipient, the composition being suitable for topical administration to a patient's skin but not suitable for administration orally or to the patient's eye.Also described are methods of treatment of various dermatological disorders comprising topical administration to the skin of a patient suffering from such a disorder of a therapeutically effective quantity of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or a pharmaceutically acceptable derivative thereof.

Abstract: Phenylquinolinecarboxylic acids and derivatives thereof, such as 2-(2'-Fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinolinecarboxylic acid, or a sodium or potassium salt thereof, are useful for the treatment of skin and muco-epithelial diseases.

Abstract: The present invention is directed to a substantially pure therapeutically active aloe isolate having a molecular weight of about 70,000 and a dialysis method for making said aloe isolate.

Abstract: The present invention relates to a preparation for the treatment of skin or scalp affections, with an exclusively plant basis, obtained by infusion in vinegar of Geum, Lavandula, Mentha, Allium, and Salvia, preferably with the addition of other plant substances having a calmative or aroma-giving action; the preparation has shown itself to be outstandingly efficacious in impeding certain conditions which promote loss of hair.

Abstract: A stable hydrocortisone-based composition comprises hydrocortisone solubilized in a mixture of an aliphatic alcohol, propyleneglycol and dimethyl coco-benzylammonium chloride.

Abstract: Mono, di and tri-esters of 1,8-dihydroxy-10-phenyl-9-anthrone or -9-anthranol have the formula ##STR1## wherein p is 0 or 1,(a) when p=0, t=1 and R.sub.2 represents hydrogen or --COR.sub.3,(b) when p=1, t=0 and R.sub.1 and R.sub.2 each independently represent hydrogen or --COR.sub.3,R.sub.3 represents linear or branched alkyl having 1-17 carbon atoms, cycloalkyl, phenyl or phenyl substituted by lower alkyl, lower alkoxy, halogen, a nitro function, --CF.sub.3 or a hydroxyl function, and mixtures of said esters. These esters are prepared by reacting 1,8-dihydroxy-10-phenyl-9-anthrone with an activated form of an acid. The esters are useful in human or veterinary medicine and in cosmetic compositions.

Abstract: A therapeutic composition for alleviating or preventing sun-induced desquamation comprises as active ingredients a C.sub.3 to C.sub.30 2-hydroxyalkanoic acid or an ester thereof together with a sunscreen active ingredient in a therapeutically acceptable vehicle. The active ingredients can also be used in the preparation of the composition for the treatment or prevention of this skin condition which can follow exposure to an excessive amount of sunlight.

Abstract: The present invention provides a composition comprising L-carnitine in a suitable vehicle for topical application in an effective amount. The present compositions are useful in improving or healing skin conditions including wrinkling, dry or peeling skin, and burns (particularly sunburn), and in healing and prevention of scar formation, particlarly that caused by infection by a pathogen. Treatment methods are also provided.

Abstract: A pharmaceutical preparation for the treatment of, e.g. ulcers, burns and skin diseases contains, as essential ingredients, from 5 to 25% by weight of Peru Balsam and from 0.01 to 0.20% by weight of silver nitrate. The preparation may be administered enterally or topically.

Abstract: Aromatic heterocyclic derivatives have the formula ##STR1## wherein R.sub.1 represents ##STR2## wherein R.sub.3 represents hydrogen, --OR.sub.4 wherein R.sub.4 represents hydrogen, alkyl having 1-20 carbon atoms or mono- or polyhydroxyalkyl or R.sub.3 represents ##STR3## wherein r' and r" represent hydrogen, lower alkyl or together form a heterocycle, R.sub.2 represents hydrogen or --CH.sub.3 and Ar represents ##STR4## wherein Z is O or S, ##STR5## wherein R.sub.5 is lower alkyl or ##STR6## wherein R.sub.6 is hydrogen or alkyl having 1-10 carbon atoms and R.sub.7 represents alkyl having 4-12 carbon atoms or cycloalkyl, Y is CH or a nitrogen atom and X represents oxygen, sulfur or --N--R.sub.8 when R.sub.8 represents hydrogen, lower alkyl or lower alkoxycarbonyl, with the proviso that (i) when Y is CH and X is oxygen or sulfur Ar is other than C and (ii) when Y is nitrogen and X is oxygen, Ar is other than (C) or (D) in which R.sub.6 is alkyl having 1-4 carbon atoms and R.sub.

Abstract: A new and improved topically applied pharmaceutical preparation for the treatment of itching, rash, eczema, insect bites, poison ivy and the like and an improved vehicle for delivering the active ingredients thereof to the human skin in a manner whereby the bioavailability and percutaneous absorption of the active ingredient is remarkably enhanced. The vehicle comprises a volatile silicone, a fatty alcohol having from 12-22 carbon atoms, hydrocortisone; and such preservatives or emulsifying agents as may be warranted.

Abstract: The invention provides a method of therapeutically treating a warm blooded animal afflicted with an autoimmune disease such as rheumatoid arthritis. In one variant, this is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M.sub.1 --O--Y, and/or an ethereal monosubstitution of monosaccharide derivatives having the general formula M.sub.2 --O--Y, and/or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In a preferred variant, a synergistic mixture is used containing one or more of the foregoing compounds as a first ingredient and an additional compatible substance as a second ingredient which is effective to therapeutically treat autoimmune diseases in warm blooded animals. The invention further provides a novel synergistic composition for therapeutically treating warm blooded animals afflicted with an autoimmune disease which consists essentially of the aforementioned first and second ingredients.

Abstract: This invention is directed to novel galenic preparation forms for providing an oral anti-diabetic agent having an improved release of active substance and to processes for producing these preparation forms. The pharmaceutical compositions are characterized in that the onset of the activity and the duration of activity are adapted to the particular needs of diabetics with regard to proper control of metabolism and the associated proper release of insulin. A basic or acidic excipient in a solvent is added to the anti-diabetically active substance in a quantity such that the active substance is made soluble, and then a solubilizing agent is added. The solution is applied to a water-insoluble carrier, the solvent is evaporated, and the residue is further processed to yield the various preparation forms.

Abstract: The oil of pips of fruits of the Ribes genus is an abundant, cheap source of .gamma.-linolenic acid.It is extracted using solvents from dried and ground residues from the production of juices, preserves and jellies or brandies, liqueurs and schnapps of fruits, such as blackcurrant, redcurrant or gooseberry. According to a preferred embodiment, the residues are treated with ethanol before being extracted with hexane in order to free the oil from most of the free fatty acids, waxes, colorings and odorous compounds.The refined oil is a valuable ingredient in cosmetic, dermatological, dietetic and pharmaceutical compositions.

Abstract: A cosmetic and pharmaceutical composition in the form of non-aqueous antimicrobial creams, lotions, and gels for topical application to the skin comprises bovine bone marrow acids mixed with lecithin for prevention of the fatty acid oxidation and odor putrefaction. The preparation of this product is accomplished without the use or incorporation of any inorganic chemicals, petroleum products, additional water. The heat treated solution provides relief for dry, flaky, and itchy skin and particularly for non-specific dermatitis and rashes.

Abstract: Improved cosmetic compositions for skin care containing an amount sufficient for skin care of glycoprotein extracts of lysed microbial bodies of Hafnia species or strains prepared by (a) cultivating a microbial Hafnia strain until complete development of microbial bodies, (b) subjecting the microbial bodies to lysis, (c) treating the lysate with at least one solvent for delipidation and depigmentation of the lysate, (d) dissolving the resulting product, (e) subjecting the solution to centrifugation and (f) optionally subjecting the resulting product to ultrafiltration and a method of improving a person's skin.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and represent a straight-chain or branched alkyl group of 1 to 15 carbon atoms, a cycloalkyl group of 3 to 6 carbon atoms, a 2-furyl, 3-furyl, 3-pyridyl, 4-pyridyl or 2-thienyl group or an aromatic group of the formula ##STR2## wherein X, Y and Z are the same or different and represent hydrogen, alkyl of 1 to 3 carbon atoms, trifluoromethyl, alkoxy with 1 to 4 carbon atoms, halogen, nitro or hydroxy groups are useful as pharmaceutical, veterinary and cosmetic agents.

Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

Abstract: A process for stimulating the growth of epidermis cells.The epidermis cells are contacted with an aqueous saline extract (RE) of ocular tissues. The process is especially applied for human epidermis cells.Application to the study of chromosomes of the human epidermis cell, particularly for the detection of natural or induced chromosome anomalies, and to the production of grafts, and especially autografts, usable on man, for example in the treatment of burns, cosmetic and diagnostic products.

Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 E.sub.4 and the slow reacting substance of anaphylaxis.As such, these compounds will be useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Abstract: Cosmetic and dermatological compositions containing 1.alpha.-hydroxycholeciferol and a suitable carrier useful in topical treatment of skin disorders and methods employing same are disclosed. Compositions containing 1.alpha.,25-dihydroxycholecalciferol and a suitable carrier and methods employing same are also disclosed for dermatological and cosmetic uses. Various formulations of the compositions including creams, lotions, ointments and sprays are disclosed for use in accordance with this invention. The compositions and formulations may contain additional active ingredients.

Abstract: There is provided a dermatological composition for treating acne and similar skin lesions which comprises benzoyl peroxide and gel from the plant Aloe vera. The gel from Aloe vera helps to reduce specific undesirable reactions which would otherwise result from the use of benzoyl peroxide to treat skin lesions.

Abstract: A pharmaceutical composition characterized in that it comprises(a) Vitamin A,(b) one or more tochopherols(c) an oil of the genus prunus, and(d) an oil of the genus sesamum;in that the weight of each of (c) and (d) is between 5 and 75 times the weight of (a); in that the weight of each of (c) and (d) is between 4 and 125 times the weight of (b); and in that the composition has a consistency suitable for topical application.

Abstract: A cosmetic composition is provided for the removal ofsebum exudate from the skin. The composition comprises immobilzed enzymes in cosmetically acceptable vehicles for topical application. The immobilized enzymes are lipolytic lipases, proteolytic proteases and enzymes for the breakdown of sugar oligomers from glucoproteins in the skin exudates. The enzymes may be present individually or in any desired combination. The enzymes are immobilized in known manners by chemical and or physical means and are released from immobilization upon application to the skin.

Abstract: Retinoic acid-4,4,18,18,18-d.sub.5 and esters and amides thereof are disclosed. These compounds are useful as chemopreventive agents for inhibiting tumor promotion in epithelial cells and for treating nonmalignant skin disorders.

Abstract: A compound of the formula: ##STR1## where X is ##STR2## and R is hydroxy, or an alkoxy with 0 or 1 hydroxy substituent, or aroxy with 0 or 1 hydroxy substituent, or alkoxy monosubstituted phenoxy, or NR.sup.1 R.sup.2 where R.sup.1 is hydrogen, or an alkyl or aryl with 0 or 1 hydroxy substituent, and R.sup.2 is an alkyl or aryl with 0 or 1 hydroxy substituent. These compounds are useful as chemopreventive agents for inhibiting tumor promotion in ephithelial cells and for treating nonmalignant skin disorders.

Abstract: Therapeutic as well as preventive measures to alleviate the symptoms of dermatologic and other conditions and disorders with phenyl alpha-acyloxyacetamide derivatives is disclosed. Dermatologic and other conditions and disorders in humans in which the compounds may be useful include pruritus, atopic dermatitis, eczema, psoriasis, acne, dry skin, dandruff, malodors of integumental areas; and various aches, pains and discomforts of skin, joints and other body parts. The phenyl alpha-acyloxyacetamide derivatives include, for example, N-ethyl phenyl alpha-acetoxyacetamide, N-benzyl phenyl-alpha-acetoxyacetamide, N-phenethyl phenyl-alpha-acetoxyacetamide, N-benzyl diphenyl-alpha-acetoxyacetamide and N-phenethyl diphenyl-alpha-acetoxyacetamide. The compositions containing the active ingredients are also useful for treatment of skin conditions or disorders, and musculoskeletal disorders, of domestic animals, for example dogs, such as dry skin, scurf, eczema, mange, prurigo, malodors, arthritis or myositis.

Abstract: The invention concerns new pharmaceutical preparations for topical administration, such as creams, ointments, foams, pastes or gels, which contain the anti-inflammatorily active glucocorticoid 2-chloro-6.alpha.,9.alpha.-difluoro-16.alpha.-methyl-11.beta.,17.alpha.,21 -trihydroxy-pregna-1,4-diene-3,20-dione (2-chloroflumethasone, halometasone) and the antimicrobial agent 2,4,4'-trichloro-2'-hydroxy-diphenyl ether (triclosan). The new dermatics may contain, besides these two components, pharmaceutical carriers as usually present in formulations for topical administration. The new dermatics are especially suitable for the treatment of inflected forms of acute eczematous dermatoses of different origin, for the initial treatment of strongly inflamed dermatomycoses or strongly inflamed forms of pyodermias.